Neurocrine Biosciences NBIX
$150.57 −$6.02 (-3.84%)
Market closed · Nov 20, 8:20 pm ET · Last extended-hours $150.57 0.00%
Open$156.27
Prev close$156.59
Day range$150.24 – $158.26
Volume1.59M
Market cap$15.24B
P/E (TTM)22.3
Dividend yield–
Fundamentals
Latest reported quarter: Q3, ended Sep 2026
Revenue$1.12B+41.2% YoY
Operating profit$343.00M+43.3% YoY
Net profit$206.50M-1.4% YoY
Diluted EPS$1.96-3.9% YoY
Free cash flow$383.60M+79.0% YoY
Operating cash flow$395.20M
Revenue, last 8 quarters
Net profit, last 8 quarters
Diluted EPS by quarter
Free cash flow by quarter
Annual revenue
Profitability & balance sheet
Gross margin97.7%
Operating margin24.6%
Net margin19.0%
Return on equity20.4%
Return on assets14.2%
Return on invested capital18.2%
Current ratio2.04
Liabilities / assets31.1%
Cash & investments$737.90M
Total debt$392.30M
Net cash (debt)$345.60M
Free cash flow / sales28.1%
Where the revenue comes from
Quarter 2026/Q3
By business line
Income statement
| Line item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 |
|---|---|---|---|---|---|
| Total Revenue as Reported | $1.12B | $959.00M | $814.50M | $2.86B | $805.50M |
| Total Operating Revenue | $1.12B | $959.00M | $814.50M | $2.86B | $805.50M |
| Cost of Revenue | $26.60M | $23.20M | $13.80M | $52.10M | $20.60M |
| Gross Profit | $1.10B | $935.80M | $800.70M | $2.81B | $784.90M |
| Operating Expense | $753.10M | $782.80M | $614.70M | $2.17B | $557.00M |
| Selling and Admin Expenses | $366.30M | $439.70M | $318.50M | $1.16B | $301.80M |
| Research & Development | $351.80M | $326.70M | $296.20M | $1.02B | $258.20M |
| Depreciation & Amortization & Depletion | $35.00M | $16.40M | – | – | – |
| -Depreciation & Amortization | $35.00M | $16.40M | – | – | – |
| Operating Profit | $343.00M | $153.00M | $186.00M | $636.50M | $227.90M |
| Net Non-Operating Interest Income (Expense) | -$300,000.00 | -$2.90M | – | $90.30M | $90.30M |
| Non-Operating Interest Expense | $300,000.00 | $2.90M | – | – | – |
| Other Income (Expense) | -$59.00M | $12.10M | $60.80M | -$21.40M | -$78.80M |
| Gain on Sale of Security | -$47.30M | $13.60M | $53.40M | -$4.00M | -$61.80M |
| Special Income (Charges) | -$11.70M | -$1.50M | $7.40M | -$17.40M | -$17.00M |
| -Less:Other Special Charges | $11.70M | $1.50M | $21.20M | $17.40M | $17.00M |
| -Gain on Sale Of Business | $0.00 | $0.00 | $28.60M | – | – |
| Pretax Profit | $283.70M | $162.20M | $246.80M | $705.40M | $239.40M |
| Tax | $77.20M | $17.80M | $48.90M | $226.80M | $85.70M |
| Net Profit | $206.50M | $144.40M | $197.90M | $478.60M | $153.70M |
| Profit from Continuing Operations | $206.50M | $144.40M | $197.90M | $478.60M | $153.70M |
| Net Income to Parent Company | $206.50M | $144.40M | $197.90M | $478.60M | $153.70M |
| Net Income to Common Stockholders | $206.50M | $144.40M | $197.90M | $478.60M | $153.70M |
| Basic EPS | $2.03 | $1.43 | $1.97 | $4.81 | $1.54 |
| Diluted EPS | $1.96 | $1.39 | $1.91 | $4.67 | $1.48 |
| Non-Operating Interest Income | – | – | – | $90.30M | – |
Balance sheet
| Line item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 |
|---|---|---|---|---|---|
| Total Assets | $5.63B | $5.36B | $4.91B | $4.63B | $4.63B |
| Total Current Assets | $2.01B | $1.64B | $2.44B | $2.52B | $2.52B |
| Cash and Cash Equivalents & Short-Term Investments | $737.90M | $389.80M | $1.32B | $1.48B | $1.48B |
| -Cash and Cash Equivalents | $641.50M | $332.40M | $266.50M | $713.00M | $713.00M |
| -Short Term Investments | $96.40M | $57.40M | $1.05B | $767.40M | $767.40M |
| Receivables | $957.30M | $887.00M | $768.10M | $686.80M | $686.80M |
| -Accounts Receivable | $957.30M | $887.00M | $768.10M | $686.80M | $686.80M |
| Prepaid Assets | $212.40M | $217.10M | $224.80M | $170.70M | $170.70M |
| Inventory | $66.10M | $104.20M | $64.50M | $69.00M | $69.00M |
| Other Current Assets | $34.50M | $39.40M | $62.50M | $115.80M | $115.80M |
| Total Non-Current Assets | $3.62B | $3.72B | $2.47B | $2.11B | $2.11B |
| Net PPE | $529.40M | $538.50M | $538.00M | $545.20M | $545.20M |
| -Gross PPE | $529.40M | $538.50M | $538.00M | $663.50M | $663.50M |
| Investments and Advances | $146.80M | $239.20M | $1.48B | $1.18B | $1.18B |
| -Available for Sale Securities | $146.80M | $239.20M | $1.48B | $1.18B | $1.18B |
| Goodwill and Other Intangible Assets | $2.69B | $2.73B | – | – | – |
| -Goodwill | $500.60M | $500.60M | – | – | – |
| -Other Intangible Assets | $2.19B | $2.23B | – | – | – |
| Non-Current Deferred Assets | $11.80M | $8.90M | $381.40M | $320.30M | $320.30M |
| Other Non-Current Assets | $239.60M | $208.40M | $73.60M | $59.50M | $59.50M |
| Total Liabilities | $1.75B | $1.67B | $1.50B | $1.38B | $1.38B |
| Total Current Liabilities | $984.60M | $874.50M | $831.70M | $743.40M | $743.40M |
| Payables | $300.60M | $256.60M | $306.40M | $172.90M | $172.90M |
| -Accounts Payable | $150.50M | $142.00M | $120.00M | $104.90M | $104.90M |
| -Total Tax Payable | $150.10M | $114.60M | $186.40M | $68.00M | $68.00M |
| Current Accrued Expenses | $137.30M | $136.40M | $153.60M | $146.60M | $146.60M |
| Current Provisions | $316.20M | $292.10M | $231.30M | $226.00M | $226.00M |
| Other Current Liabilities | $61.20M | $66.20M | $58.70M | $69.10M | $69.10M |
| Total Non-Current Liabilities | $764.10M | $791.00M | $667.10M | $635.00M | $635.00M |
| Long Term Accounts Payable and Other Payables | $266.60M | $262.20M | $241.30M | $214.50M | $214.50M |
| Long Term Debt and Capital Lease Obligation | $392.30M | $401.80M | $406.20M | $415.30M | $415.30M |
| -Long Term Capital Lease Obligation | $392.30M | $401.80M | $406.20M | $415.30M | $415.30M |
| Non-Current Deferred Liabilities | $105.00M | $91.50M | – | – | – |
| Other Non-Current Liabilities | $200,000.00 | $35.50M | $19.60M | $5.20M | $5.20M |
| Total Equity | $3.88B | $3.69B | $3.41B | $3.25B | $3.25B |
| Stockholders' Equity | $3.88B | $3.69B | $3.41B | $3.25B | $3.25B |
| Capital Stock | $100,000.00 | $100,000.00 | $100,000.00 | $100,000.00 | $100,000.00 |
| -Common Stock | $100,000.00 | $100,000.00 | $100,000.00 | $100,000.00 | $100,000.00 |
| -Preferred Stock | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Additional Paid-In Capital | $3.04B | $2.96B | $2.82B | $2.79B | $2.79B |
| Retained Earnings | $838.40M | $724.00M | $589.60M | $447.70M | $447.70M |
| Gains/Losses Not Affecting Retained Earnings | $4.40M | $5.10M | $400,000.00 | $13.10M | $13.10M |
| -Accumulated Depreciation | – | – | – | -$118.30M | -$118.30M |
Cash flow
| Line item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 |
|---|---|---|---|---|---|
| Operating Cash Flow | $395.20M | $136.40M | $145.80M | $782.70M | $388.40M |
| Net cash flow from continuing operations | $395.20M | $136.40M | $145.80M | $782.70M | $388.40M |
| Net Income from Continuing Operations | $206.50M | $144.40M | $197.90M | $478.60M | $153.70M |
| Gain/Loss from Continuing Operations | $0.00 | $5.20M | -$28.60M | – | – |
| Depreciation & Depletion & Amortization | $44.00M | $24.80M | $7.30M | $30.10M | $7.50M |
| Deferred Tax | $10.60M | -$25.30M | -$61.10M | $165.40M | $48.20M |
| Other Non-Cash Items | $7.60M | $3.60M | $1.40M | $14.80M | $3.20M |
| Change in Working Capital | $19.90M | -$80.10M | -$3.00M | -$128.80M | $119.20M |
| -Change in Receivables | -$70.20M | -$84.30M | -$81.40M | -$210.50M | $38.40M |
| -Change in Inventory | $3.30M | -$6.50M | $4.30M | -$15.30M | -$3.40M |
| -Change in Payables and Accrued Expense | $76.80M | -$8.50M | -$14.30M | $160.20M | $76.50M |
| -Change In Other Working Capital | $10.00M | $19.20M | $88.40M | -$63.20M | $7.70M |
| Net cash flow from investing | -$11.10M | -$135.40M | -$506.20M | -$264.40M | -$52.90M |
| Net Cash Flow from Continuing Investing Activities | -$11.10M | -$135.40M | -$506.20M | -$264.40M | -$52.90M |
| Capital Expenditure | -$11.60M | -$7.80M | -$9.10M | -$34.00M | $2.40M |
| Net Business Purchase and Sale | $0.00 | -$2.36B | $63.20M | – | – |
| Net Investment Purchase and Sale | $500,000.00 | $2.23B | -$560.30M | -$230.40M | -$55.30M |
| Financing Cash Flow | -$75.00M | $63.40M | -$86.10M | -$38.30M | $37.30M |
| Net Cash Flow from Continuing Financing Activities | -$75.00M | $63.40M | -$86.10M | -$38.30M | $37.30M |
| Net Issuance Payments Of Debt | $0.00 | – | – | $0.00 | $0.00 |
| Net Common Stock Issuance | -$92.10M | -$12.00M | -$54.00M | -$167.70M | $0.00 |
| Proceeds from Stock Option Exercised | $25.30M | $84.80M | $23.60M | $129.40M | $37.30M |
| Net Other Financing Charges | -$8.20M | -$9.40M | -$55.70M | – | – |
| Ending Cash Balance | $648.00M | $338.90M | $274.50M | $721.00M | $721.00M |
| Net Change in Cash | $309.10M | $64.40M | -$446.50M | $480.00M | $372.80M |
| Beginning Cash Balance | $338.90M | $274.50M | $721.00M | $241.00M | $348.20M |
| Free Cash Flow | $383.60M | $128.60M | $136.70M | $748.70M | $390.80M |
| Effect of Exchange Rate Changes | – | – | – | $0.00 | $0.00 |
No comments yet — be the first to weigh in on NBIX.
Sign in to join the discussion.